{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:55:10Z","timestamp":1794567310629,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":260,"publisher":"Springer New York","isbn-type":[{"value":"9781493978243","type":"print"},{"value":"9781493978250","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-7825-0_17","type":"book-chapter","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T08:44:16Z","timestamp":1527756256000},"page":"329-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Biofluid Biomarkers in Huntington\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Filipe B.","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"17_CR1","first-page":"S365","volume":"31","author":"AM Travessa","year":"2016","unstructured":"Travessa AM, Rodrigues FB, Mestre TA et al (2016) Fifteen years of clinical trials in Huntington\u2019s disease: too many clinical trial failures. Mov Disord 31:S365\u2013S366","journal-title":"Mov Disord"},{"key":"17_CR2","doi-asserted-by":"crossref","unstructured":"Mestre T, Ferreira J, Coelho MM et al (2009) Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease. Cochrane Database Syst Rev (3):Cd006456","DOI":"10.1002\/14651858.CD006456.pub2"},{"key":"17_CR3","unstructured":"Rodrigues FB, Mestre T, Duarte SD et al (2017) [122] Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease\u00a0\u2013 a Cochrane review. In: CHDI (ed) CHDI 12th annual HD therapeutics conference, St Julien, Malta, 2017"},{"key":"17_CR4","doi-asserted-by":"crossref","unstructured":"Mestre T, Ferreira J, Coelho MM et al (2009) Therapeutic interventions for disease progression in Huntington\u2019s disease. Cochrane Database Syst Rev (3):Cd006455","DOI":"10.1002\/14651858.CD006455.pub2"},{"key":"17_CR5","unstructured":"Rodrigues FB, Mestre T, Duarte SD et al (2017) [121] Therapeutic interventions for disease progression in Huntington\u2019s disease\u00a0\u2013 a Cochrane review. In: CHDI 12th annual HD therapeutics conference, St Julien, Malta, 2017"},{"key":"17_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ebiom.2016.05.023","volume":"8","author":"EJ Wild","year":"2016","unstructured":"Wild EJ (2016) Huntington\u2019s disease: the most curable incurable brain disorder? EBioMedicine 8:3\u20134","journal-title":"EBioMedicine"},{"issue":"3","key":"17_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3233\/JHD-170262","volume":"6","author":"FB Rodrigues","year":"2017","unstructured":"Rodrigues FB, Wild EJ (2017) Clinical trials corner: September 2017. J Huntingtons Dis 6(3):255\u2013263. https:\/\/doi.org\/10.3233\/JHD-170262","journal-title":"J Huntingtons Dis"},{"issue":"1","key":"17_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JHD-189001","volume":"7","author":"FB Rodrigues","year":"2018","unstructured":"Rodrigues FB, Wild EJ (2018) Huntignton's disease clinical trials corner: February 2018. J Huntingtons Dis 7(1):89\u201398. https:\/\/doi.org\/10.3233\/JHD-189001","journal-title":"J Huntingtons Dis"},{"key":"17_CR9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10:204\u2013216","journal-title":"Nat Rev Neurol"},{"key":"17_CR10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi SJ, Scahill RI, Owen G et al (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12:637\u2013649","journal-title":"Lancet Neurol"},{"key":"17_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fnagi.2013.00012","volume":"5","author":"KM Biglan","year":"2013","unstructured":"Biglan KM, Zhang Y, Long JD et al (2013) Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci 5:12. https:\/\/doi.org\/10.3389\/fnagi.2013.00012","journal-title":"Front Aging Neurosci"},{"key":"17_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-160196","volume":"5","author":"LM Byrne","year":"2016","unstructured":"Byrne LM, Wild EJ (2016) Cerebrospinal fluid biomarkers for Huntington\u2019s disease. J Huntingtons Dis 5:1\u201313","journal-title":"J Huntingtons Dis"},{"key":"17_CR13","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72:971\u2013983","journal-title":"Cell"},{"key":"17_CR14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/306234a0","volume":"306","author":"JF Gusella","year":"1983","unstructured":"Gusella JF, Wexler NS, Conneally PM et al (1983) A polymorphic DNA marker genetically linked to Huntington\u2019s disease. Nature 306:234\u2013238","journal-title":"Nature"},{"key":"17_CR15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","volume":"6","author":"E Cattaneo","year":"2005","unstructured":"Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington\u2019s disease. Nat Rev Neurosci 6:919\u2013930","journal-title":"Nat Rev Neurosci"},{"key":"17_CR16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jmb.2012.01.030","volume":"421","author":"R Wetzel","year":"2012","unstructured":"Wetzel R (2012) Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. J Mol Biol 421:466\u2013449","journal-title":"J Mol Biol"},{"key":"17_CR17","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1172\/JCI64565","volume":"122","author":"A Weiss","year":"2012","unstructured":"Weiss A, Tr\u00e4ger U, Wild EJ et al (2012) Mutant huntingtin fragmentation in immune cells tracks Huntington\u2019s disease progression. J Clin Investig 122:3731\u20133736","journal-title":"J Clin Investig"},{"key":"17_CR18","doi-asserted-by":"crossref","DOI":"10.1371\/currents.RRN1205","volume":"2","author":"M Moscovitch-Lopatin","year":"2010","unstructured":"Moscovitch-Lopatin M, Weiss A, Rosas HD et al (2010) Optimization of an HTRF assay for the detection of soluble mutant huntingtin in human buffy coats: a potential biomarker in blood for Huntington disease. PLoS Curr 2:Rrn1205","journal-title":"PLoS Curr"},{"key":"17_CR19","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/WNL.0b013e3182a55ede","volume":"81","author":"M Moscovitch-Lopatin","year":"2013","unstructured":"Moscovitch-Lopatin M, Goodman RE, Eberly S et al (2013) HTRF analysis of soluble huntingtin in PHAROS PBMCs. Neurology 81:1134\u20131140","journal-title":"Neurology"},{"key":"17_CR20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2091-14-34","volume":"14","author":"L Massai","year":"2013","unstructured":"Massai L, Petricca L, Magnoni L et al (2013) Development of an ELISA assay for the quantification of soluble huntingtin in human blood cells. BMC Biochem 14:34","journal-title":"BMC Biochem"},{"key":"17_CR21","doi-asserted-by":"crossref","first-page":"12166","DOI":"10.1038\/srep12166","volume":"5","author":"AL Southwell","year":"2015","unstructured":"Southwell AL, Smith SEP, Davis TR et al (2015) Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci Rep 5:12166","journal-title":"Sci Rep"},{"key":"17_CR22","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild EJ, Boggio R, Langbehn D et al (2015) Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J Clin Investig 125:1979\u20131986","journal-title":"J Clin Investig"},{"key":"17_CR23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ab.2009.08.001","volume":"395","author":"A Weiss","year":"2009","unstructured":"Weiss A, Abramowski D, Bibel M et al (2009) Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington\u2019s disease. Anal Biochem 395:8\u201315","journal-title":"Anal Biochem"},{"key":"17_CR24","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/cbic.200900131","volume":"10","author":"P Paganetti","year":"2009","unstructured":"Paganetti P, Weiss A, Trapp M et al (2009) Development of a method for the high-throughput quantification of cellular proteins. Chembiochem 10:1678\u20131688","journal-title":"Chembiochem"},{"key":"17_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JHD-170269","volume":"6","author":"V Fodale","year":"2017","unstructured":"Fodale V, Boggio R, Daldin M et al (2017) Validation of ultrasensitive mutant huntingtin detection in human cerebrospinal fluid by single molecule counting immunoassay. J Huntingtons Dis 6:349\u2013361. https:\/\/doi.org\/10.3233\/JHD-170269","journal-title":"J Huntingtons Dis"},{"key":"17_CR26","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archneurpsyc.1927.02210060002001","volume":"18","author":"CB Dunlap","year":"1927","unstructured":"Dunlap CB (1927) Pathologic changes in Huntington\u2019s chorea: with special reference to the corpus striatum. Arch Neurol Psychiatr 18:867\u2013943","journal-title":"Arch Neurol Psychiatr"},{"key":"17_CR27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00344209","volume":"13","author":"CF Terrence","year":"1977","unstructured":"Terrence CF, Delaney JF, Alberts MC (1977) Computed tomography for Huntington\u2019s disease. Neuroradiology 13:173\u2013175","journal-title":"Neuroradiology"},{"key":"17_CR28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","volume":"8","author":"SJ Tabrizi","year":"2009","unstructured":"Tabrizi SJ, Langbehn DR, Leavitt BR et al (2009) Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8:791\u2013801","journal-title":"Lancet Neurol"},{"key":"17_CR29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","volume":"10","author":"SJ Tabrizi","year":"2011","unstructured":"Tabrizi SJ, Scahill RI, Durr A et al (2011) Biological and clinical changes in premanifest and early stage Huntington\u2019s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10:31\u201342","journal-title":"Lancet Neurol"},{"key":"17_CR30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi SJ, Reilmann R, Roos RAC et al (2012) Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11:42\u201353","journal-title":"Lancet Neurol"},{"key":"17_CR31","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","volume":"79","author":"JS Paulsen","year":"2008","unstructured":"Paulsen JS, Langbehn DR, Stout JC et al (2008) Detection of Huntington\u2019s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79:874\u2013880","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"17_CR32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.parkreldis.2008.05.012","volume":"15","author":"R Constantinescu","year":"2009","unstructured":"Constantinescu R, Romer M, Oakes D et al (2009) Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington\u2019s disease. Parkinsonism Relat Disord 15:245\u2013248","journal-title":"Parkinsonism Relat Disord"},{"key":"17_CR33","first-page":"S353","volume":"31","author":"FB Rodrigues","year":"2016","unstructured":"Rodrigues FB, Byrne LM, Tabrizi SJ et al (2016) CSF inflammatory and cell death biomarkers in Huntington\u2019s disease\u00a0\u2013 an exploratory cross-sectional study. Mov Disord 31:S353","journal-title":"Mov Disord"},{"key":"17_CR34","volume":"12","author":"V Niemela","year":"2017","unstructured":"Niemela V, Landtblom AM, Blennow K, Sundblom J (2017) Tau or neurofilament light\u2014which is the more suitable biomarker for Huntington\u2019s disease? PLoS One 12:e0172762","journal-title":"PLoS One"},{"key":"17_CR35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne LM, Rodrigues FB, Blennow K et al (2017) Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis. Lancet Neurol 16:601\u2013609","journal-title":"Lancet Neurol"},{"key":"17_CR36","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1212\/NXI.0000000000000287","volume":"3","author":"T Vinther-Jensen","year":"2016","unstructured":"Vinther-Jensen T, B\u00f6rnsen L, Budtz-J\u00f8rgensen E, Ammitzb\u00f8ll C, Larsen IU, Hjermind LE, Sellebjerg F, Nielsen JE (2016) Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurol Neuroimmunol Neuroinflamm 3:e287. https:\/\/doi.org\/10.1212\/NXI.0000000000000287","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"17_CR37","doi-asserted-by":"publisher","first-page":"e0193492","DOI":"10.1371\/journal.pone.0193492","volume":"13","author":"V Niemel\u00e4","year":"2018","unstructured":"Niemel\u00e4 V, Burman J, Blennow K, Zetterberg H, Larsson A, Sundblom J (2018) Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington\u2019s disease. PLoS One 13:e0193492. https:\/\/doi.org\/10.1371\/journal.pone.0193492","journal-title":"PLoS One"},{"key":"17_CR38","doi-asserted-by":"publisher","first-page":"e717","DOI":"10.1212\/WNL.0000000000005005","volume":"90","author":"EB Johnson","year":"2018","unstructured":"Johnson EB, Byrne LM, Gregory S et al (2018) Neurofilament light protein in blood predictsregional atrophy in Huntington disease. Neurology 90:e717\u2013e723. https:\/\/doi.org\/10.1212\/WNL.0000000000005005","journal-title":"Neurology"},{"key":"17_CR39","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neulet.2007.02.053","volume":"417","author":"EJ Wild","year":"2007","unstructured":"Wild EJ, Petzold A, Keir G, Tabrizi SJ (2007) Plasma neurofilament heavy chain levels in Huntington\u2019s disease. Neurosci Lett 417:231\u2013233","journal-title":"Neurosci Lett"},{"key":"17_CR40","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.parkreldis.2011.06.010","volume":"17","author":"R Constantinescu","year":"2011","unstructured":"Constantinescu R, Romer M, Zetterberg H et al (2011) Increased levels of total tau protein in the cerebrospinal fluid in Huntington\u2019s disease. Parkinsonism Relat Disord 17:714\u2013715","journal-title":"Parkinsonism Relat Disord"},{"key":"17_CR41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jnc.13719","volume":"139","author":"FB Rodrigues","year":"2016","unstructured":"Rodrigues FB, Byrne L, McColgan P et al (2016) Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington\u2019s disease. J Neurochem 139:22\u201325","journal-title":"J Neurochem"},{"key":"17_CR42","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","volume":"93","author":"N Stoy","year":"2005","unstructured":"Stoy N, Mackay GM, Forrest CM et al (2005) Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem 93:611\u2013623","journal-title":"J Neurochem"},{"key":"17_CR43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JHD-130049","volume":"2","author":"E Silajdzic","year":"2013","unstructured":"Silajdzic E, Rezeli M, Vegvari A et al (2013) A critical evaluation of inflammatory markers in Huntington\u2019s disease plasma. J Huntingtons Dis 2:125\u2013134","journal-title":"J Huntingtons Dis"},{"key":"17_CR44","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.parkreldis.2014.08.011","volume":"20","author":"T Vinther-Jensen","year":"2014","unstructured":"Vinther-Jensen T, Budtz-J\u00f8rgensen E, Simonsen AH, Nielsen JE, Hjermind LE (2014) YKL-40 in cerebrospinal fluid in Huntington\u2019s disease--a role in pathology or a nonspecific response to inflammation? Parkinsonism Relat Disord 20:1301\u20131303","journal-title":"Parkinsonism Relat Disord"},{"key":"17_CR45","doi-asserted-by":"crossref","first-page":"7611","DOI":"10.1073\/pnas.86.19.7611","volume":"86","author":"WS Griffin","year":"1989","unstructured":"Griffin WS, Stanley LC, Ling C et al (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86:7611\u20137615","journal-title":"Proc Natl Acad Sci U S A"},{"key":"17_CR46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","volume":"233","author":"A Petzold","year":"2005","unstructured":"Petzold A (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 233:183\u2013198","journal-title":"J Neurol Sci"},{"key":"17_CR47","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/path.1650","volume":"204","author":"NJ Cairns","year":"2004","unstructured":"Cairns NJ, Lee VM, Trojanowski JQ (2004) The cytoskeleton in neurodegenerative diseases. J Pathol 204:438\u2013449","journal-title":"J Pathol"},{"key":"17_CR48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrneurol.2013.9","volume":"9","author":"H Zetterberg","year":"2013","unstructured":"Zetterberg H, Smith DH, Blennow K (2013) Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol 9:201\u2013210","journal-title":"Nat Rev Neurol"},{"key":"17_CR49","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nm.3617","volume":"20","author":"M Fernandez-Nogales","year":"2014","unstructured":"Fernandez-Nogales M, Cabrera JR, Santos-Galindo M et al (2014) Huntington\u2019s disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 20:881\u2013885","journal-title":"Nat Med"},{"key":"17_CR50","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/brain\/awv107","volume":"138","author":"R Vuono","year":"2015","unstructured":"Vuono R, Winder-Rhodes S, de Silva R et al (2015) The role of tau in the pathological process and clinical expression of Huntington\u2019s disease. Brain 138:1907\u20131918","journal-title":"Brain"},{"key":"17_CR51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","volume":"3","author":"M Gisslen","year":"2016","unstructured":"Gisslen M, Price RW, Andreasson U et al (2016) Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3:135\u2013140","journal-title":"EBioMedicine"},{"key":"17_CR52","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1212\/WNL.0000000000003688","volume":"88","author":"P Steinacker","year":"2017","unstructured":"Steinacker P, Semler E, Anderl-Straub S et al (2017) Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology 88:961\u2013969","journal-title":"Neurology"},{"key":"17_CR53","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/acn3.290","volume":"3","author":"JC Rojas","year":"2016","unstructured":"Rojas JC, Karydas A, Bang J et\u00a0al (2016) Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 3:216\u2013225","journal-title":"Ann Clin Transl Neurol"},{"key":"17_CR54","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","volume":"87","author":"JD Rohrer","year":"2016","unstructured":"Rohrer JD, Woollacott IO, Dick KM et al (2016) Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87:1329\u20131336","journal-title":"Neurology"},{"key":"17_CR55","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/acn3.325","volume":"3","author":"LH Meeter","year":"2016","unstructured":"Meeter LH, Dopper EG, Jiskoot LC et al (2016) Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 3:623\u2013636","journal-title":"Ann Clin Transl Neurol"},{"key":"17_CR56","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","volume":"84","author":"CH Lu","year":"2015","unstructured":"Lu CH, Macdonald-Wallis C, Gray E et al (2015) Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84:2247\u20132257","journal-title":"Neurology"},{"key":"17_CR57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075091","volume":"8","author":"J Gaiottino","year":"2013","unstructured":"Gaiottino J, Norgren N, Dobson R et al (2013) Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 8:e75091","journal-title":"PLoS One"},{"key":"17_CR58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neuron.2009.09.034","volume":"64","author":"M Bj\u00f6rkqvist","year":"2009","unstructured":"Bj\u00f6rkqvist M, Wild EJ, Tabrizi SJ (2009) Harnessing immune alterations in neurodegenerative diseases. Neuron 64:21\u201324","journal-title":"Neuron"},{"key":"17_CR59","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/pr0700753","volume":"6","author":"A Dalrymple","year":"2007","unstructured":"Dalrymple A, Wild EJ, Joubert R et al (2007) Proteomic profiling of plasma in Huntington\u2019s disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 6:2833\u20132840","journal-title":"J Proteome Res"},{"key":"17_CR60","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/hmg\/ddw262","volume":"25","author":"JR Miller","year":"2016","unstructured":"Miller JR, Lo KK, Andre R et al (2016) RNA-Seq of Huntington\u2019s disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. Hum Mol Genet 25:2893\u20132904","journal-title":"Hum Mol Genet"},{"key":"17_CR61","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/mds.26007","volume":"29","author":"EJ Wild","year":"2014","unstructured":"Wild EJ, Tabrizi SJ (2014) Targets for future clinical trials in Huntington\u2019s disease: What's in the pipeline? Mov Disord 29:1434\u20131445","journal-title":"Mov Disord"},{"key":"17_CR62","unstructured":"A Clinical Study in Subjects With Huntington\u2019s Disease to Assess the Efficacy and Safety of Three Oral Doses of Laquinimod (2014) Bethesda (MD): National Library of Medicine (US). https:\/\/ClinicalTrials.gov\/show\/NCT02215616 . Accessed 02 Mar 2016"},{"key":"17_CR63","volume":"11","author":"FB Rodrigues","year":"2016","unstructured":"Rodrigues FB, Byrne LM, McColgan P et al (2016) Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington\u2019s disease. PLoS One 11:e0163479","journal-title":"PLoS One"},{"key":"17_CR64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000647","volume":"2","author":"F Mochel","year":"2007","unstructured":"Mochel F, Charles P, Seguin F et al (2007) Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2:e647","journal-title":"PLoS One"},{"key":"17_CR65","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bj\u00f6rkqvist","year":"2008","unstructured":"Bj\u00f6rkqvist M, Wild EJ, Thiele J et\u00a0al (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. J Exp Med 205:1869\u20131877","journal-title":"J Exp Med"},{"key":"17_CR66","first-page":"231","volume":"5","author":"R Wang","year":"2014","unstructured":"Wang R, Ross CA, Cai H et al (2014) Metabolic and hormonal signatures in pre-manifest and manifest Huntington\u2019s disease patients. Front Physiol 5:231","journal-title":"Front Physiol"},{"key":"17_CR67","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1515\/CCLM.1998.132","volume":"36","author":"F Leblhuber","year":"1998","unstructured":"Leblhuber F, Walli J, Jellinger K et al (1998) Activated immune system in patients with Huntington\u2019s disease. Clin Chem Lab Med 36:747\u2013750","journal-title":"Clin Chem Lab Med"},{"key":"17_CR68","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1179\/1743132812Y.0000000073","volume":"34","author":"F Sanchez-Lopez","year":"2012","unstructured":"Sanchez-Lopez F, Tasset I, Aguera E et al (2012) Oxidative stress and inflammation biomarkers in the blood of patients with Huntington\u2019s disease. Neurol Res 34:721\u2013724","journal-title":"Neurol Res"},{"key":"17_CR69","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/brain\/awt355","volume":"137","author":"U Trager","year":"2014","unstructured":"Trager U, Andre R, Lahiri N et al (2014) HTT-lowering reverses Huntington\u2019s disease immune dysfunction caused by NF B pathway dysregulation. Brain 137:819\u2013833","journal-title":"Brain"},{"key":"17_CR70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","volume":"44","author":"K-H Chang","year":"2015","unstructured":"Chang K-H, Wu Y-R, Chen Y-C, Chen C-M (2015) Plasma inflammatory biomarkers for Huntington\u2019s disease patients and mouse model. Brain Behav Immun 44:121\u2013127","journal-title":"Brain Behav Immun"},{"key":"17_CR71","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1471-4159.2009.06442.x","volume":"112","author":"CM Forrest","year":"2010","unstructured":"Forrest CM, Mackay GM, Stoy N et al (2010) Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington\u2019s disease. J Neurochem 112:112\u2013122","journal-title":"J Neurochem"},{"key":"17_CR72","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-009-1103-3","volume":"36","author":"F Squitieri","year":"2009","unstructured":"Squitieri F, Orobello S, Cannella M et al (2009) Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging 36:1113\u20131120","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"17_CR73","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1582-4934.2010.01011.x","volume":"15","author":"G Battaglia","year":"2011","unstructured":"Battaglia G, Cannella M, Riozzi B et al (2011) Early defect of transforming growth factor beta1 formation in Huntington\u2019s disease. J Cell Mol Med 15:555\u2013571","journal-title":"J Cell Mol Med"},{"key":"17_CR74","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12017-011-8147-9","volume":"13","author":"N Mattsson","year":"2011","unstructured":"Mattsson N, Tabatabaei S, Johansson P et al (2011) Cerebrospinal fluid microglial markers in Alzheimer\u2019s disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med 13:151\u2013159","journal-title":"Neuromolecular Med"},{"key":"17_CR75","doi-asserted-by":"publisher","unstructured":"Byrne LM, Rodrigues FB, Johnson EB, De Vita E, Blennow K, Scahill R, Zetterberg H, Heslegrave A, Wild EJ (2018) Cerebrospinal fluid neurogranin and TREM2 in Huntington\u2019s disease. Sci Rep. 8. https:\/\/doi.org\/10.1038\/s41598-018-21788-x","DOI":"10.1038\/s41598-018-21788-x"},{"key":"17_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015809","volume":"6","author":"Y-C Huang","year":"2011","unstructured":"Huang Y-C, Wu Y-R, Tseng M-Y et al (2011) Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington\u2019s disease. PLoS One 6:e15809. https:\/\/doi.org\/10.1371\/journal.pone.0015809","journal-title":"PLoS One"},{"key":"17_CR77","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1471-4159.2006.03807.x","volume":"97","author":"J Christofides","year":"2006","unstructured":"Christofides J, Bridel M, Egerton M et al (2006) Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington\u2019s disease or chronic brain injury. J Neurochem 97:1078\u20131088","journal-title":"J Neurochem"},{"key":"17_CR78","doi-asserted-by":"crossref","DOI":"10.1371\/currents.RRN1231","volume":"3","author":"E Wild","year":"2011","unstructured":"Wild E, Magnusson A, Lahiri N et al (2011) Abnormal peripheral chemokine profile in Huntington\u2019s disease. PLoS Curr 3:RRN1231","journal-title":"PLoS Curr"},{"key":"17_CR79","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10863-012-9479-3","volume":"45","author":"J Krzyszton-Russjan","year":"2013","unstructured":"Krzyszton-Russjan J, Zielonka D, Jackiewicz J et\u00a0al (2013) A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington\u2019s disease: looking for biomarkers. J Bioenerg Biomembr 45:71\u201385","journal-title":"J Bioenerg Biomembr"},{"key":"17_CR80","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.euroneuro.2014.05.004","volume":"24","author":"JA Bouwens","year":"2014","unstructured":"Bouwens JA, Hubers AA, van Duijn E et al (2014) Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington\u2019s disease. Eur Neuropsychopharmacol 24:1248\u20131256","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1\u20132","key":"17_CR81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2011.12.014","volume":"315","author":"I Tasset","year":"2012","unstructured":"Tasset I, Sanchez-Lopez F, Aguera E et al (2012) NGF and nitrosative stress in patients with Huntington\u2019s disease. J Neurol Sci 315(1\u20132):133\u2013136","journal-title":"J Neurol Sci"},{"key":"17_CR82","first-page":"311","volume":"52","author":"OT Phillipson","year":"1977","unstructured":"Phillipson OT, Bird ED (1977) Plasma glucose, non-esterified fatty acids and amino acids in Huntington\u2019s chorea. Clin Sci Mol Med 52:311\u2013318","journal-title":"Clin Sci Mol Med"},{"key":"17_CR83","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00702-009-0364-0","volume":"117","author":"R Duran","year":"2010","unstructured":"Duran R, Barrero FJ, Morales B et al (2010) Oxidative stress and plasma aminopeptidase activity in Huntington\u2019s disease. J Neural Transm 117:325\u2013332","journal-title":"J Neural Transm"},{"key":"17_CR84","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.nbd.2010.08.009","volume":"40","author":"K Josefsen","year":"2010","unstructured":"Josefsen K, Nielsen SM, Campos A et al (2010) Reduced gluconeogenesis and lactate clearance in Huntington\u2019s disease. Neurobiol Dis 40:656\u2013662","journal-title":"Neurobiol Dis"},{"key":"17_CR85","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-60327-407-4","volume-title":"Enzymatic analysis: a practical guide","author":"J Passonneau","year":"1993","unstructured":"Passonneau J, Lowry O (1993) Enzymatic analysis: a practical guide. Humana Press, NJ"},{"key":"17_CR86","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mds.23258","volume":"26","author":"A Ciammola","year":"2011","unstructured":"Ciammola A, Sassone J, Sciacco M et al (2011) Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington\u2019s disease. Mov Disord 26:130\u2013137","journal-title":"Mov Disord"},{"key":"17_CR87","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000096887","volume":"2","author":"WA Banks","year":"1995","unstructured":"Banks WA, Plotkin SR, Kastin AJ (1995) Permeability of the blood-brain barrier to soluble cytokine receptors. Neuroimmunomodulation 2:161\u2013165","journal-title":"Neuroimmunomodulation"},{"key":"17_CR88","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1021\/ci970236v","volume":"37","author":"NN Aronson","year":"1997","unstructured":"Aronson NN, Blanchard CJ, Madura JD (1997) Homology modeling of glycosyl hydrolase family 18 enzymes and proteins. J Chem Inf Comput Sci 37:999\u20131005","journal-title":"J Chem Inf Comput Sci"},{"key":"17_CR89","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1750-3639.2011.00550.x","volume":"22","author":"D Bonneh-Barkay","year":"2012","unstructured":"Bonneh-Barkay D, Bissel SJ, Kofler J et\u00a0al (2012) Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol 22:530\u2013546","journal-title":"Brain Pathol"},{"key":"17_CR90","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0197-0186(01)00058-4","volume":"40","author":"AJL Cooper","year":"2002","unstructured":"Cooper AJL, Jeitner TM, Gentile V, Blass JP (2002) Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)n\/Qn-expansion diseases? Neurochem Int 40:53\u201367","journal-title":"Neurochem Int"},{"key":"17_CR91","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1471-4159.2001.00673.x","volume":"79","author":"TM Jeitner","year":"2008","unstructured":"Jeitner TM, Bogdanov MB, Matson WR et al (2008) N\u03b5-(\u03b3-l-Glutamyl)-l-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington\u2019s disease. J Neurochem 79:1109\u20131112","journal-title":"J Neurochem"},{"key":"17_CR92","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1471-4159.2008.05350.x","volume":"106","author":"TM Jeitner","year":"2008","unstructured":"Jeitner TM, Matson WR, Folk JEBlass JP, Cooper AJL (2008) Increased levels of \u03b3-glutamylamines in Huntington disease CSF. J Neurochem 106:37\u201344","journal-title":"J Neurochem"},{"key":"17_CR93","unstructured":"Raptor Plans to Advance RP103 in a Registration Study in Huntington\u2019s Disease Based on Favorable Treatment Effects at 36 Months in CYST-HD Trial (2015). http:\/\/www.prnewswire.com\/news-releases\/raptor-plans-to-advance-rp103-in-a-registration-study-in-huntingtons-disease-based-on-favorable-treatment-effects-at-36-months-in-cyst-hd-trial-300191131.html"},{"key":"17_CR94","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1471-4159.1977.tb10676.x","volume":"28","author":"SJ Enna","year":"1977","unstructured":"Enna SJ, Wood JH, Snyder SH (1977) \u03b3-Aminobutyric acid (GABA) in human cerebrospinal fluid: radioreceptor assay. J Neurochem 28:1121\u20131124","journal-title":"J Neurochem"},{"key":"17_CR95","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/archneur.1978.00500350032006","volume":"35","author":"NV Manyam","year":"1978","unstructured":"Manyam NV, Hare TA, Katz L, Glaeser BS (1978) Huntington\u2019s disease. Cerebrospinal fluid GABA levels in at-risk individuals. Arch Neurol 35:728\u2013730","journal-title":"Arch Neurol"},{"key":"17_CR96","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0024-3205(80)90244-1","volume":"26","author":"P B\u00f6hlen","year":"1980","unstructured":"B\u00f6hlen P, Tell G, Schechter PJ et al (1980) Cerebrospinal fluid homocarnosine in Huntington\u2019s disease. Life Sci 26:1009\u20131012","journal-title":"Life Sci"},{"key":"17_CR97","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1600-0404.1986.tb03511.x","volume":"74","author":"S Uhlhaas","year":"1986","unstructured":"Uhlhaas S, Lange H, Wappenschmidt J, Olek K (1986) Free and conjugated CSF and plasma GABA in Huntington\u2019s chorea. Acta Neurol Scand 74:261\u2013265","journal-title":"Acta Neurol Scand"},{"key":"17_CR98","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mds.870020206","volume":"2","author":"AM Bonnet","year":"1987","unstructured":"Bonnet AM, Tell G, Schechter PJ et al (1987) Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich\u2019s ataxia, Parkinson\u2019s disease, and Huntington\u2019s chorea. Mov Disord 2:117\u2013123","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"17_CR99","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0304-3940(93)90168-K","volume":"154","author":"F Nicoli","year":"1993","unstructured":"Nicoli F, Vion-Dury J, Maloteaux JM et al (1993) CSF and serum metabolic profile of patients with Huntington\u2019s chorea: a study by high resolution proton NMR spectroscopy and HPLC. Neurosci Lett 154(1\u20132):47\u201351","journal-title":"Neurosci Lett"},{"key":"17_CR100","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jnc.13624","volume":"137","author":"L Wagner","year":"2016","unstructured":"Wagner L, Bjorkqvist M, Lundh SH et al (2016) Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington\u2019s disease: increased NPY levels and differential degradation of the NPY fragment. J Neurochem 137:820\u2013837","journal-title":"J Neurochem"},{"key":"17_CR101","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00342343","volume":"223","author":"S Consolo","year":"1977","unstructured":"Consolo S, Ladinsky H, Bianchi S, Caraceni T (1977) The cerebrospinal fluid choline levels in patients with Huntington\u2019s chorea. Negative effect of haloperidol treatment. Arch Psychiatr Nervenkr 223:265\u2013270","journal-title":"Arch Psychiatr Nervenkr"},{"key":"17_CR102","first-page":"279","volume":"186","author":"JK Saelens","year":"1970","unstructured":"Saelens JK, Allen MP, Simke JP (1970) Determination of acetylcholine and choline by an enzymatic assay. Arch Int Pharmacodyn Ther 186:279\u2013286","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"17_CR103","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00314742","volume":"237","author":"BV Manyam","year":"1990","unstructured":"Manyam BV, Giacobini E, Colliver JA (1990) Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington\u2019s disease. J Neurol 237:281\u2013284","journal-title":"J Neurol"},{"key":"17_CR104","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0024-3205(68)90017-9","volume":"7","author":"MW McCaman","year":"1968","unstructured":"McCaman MW, Tomey LR, McCaman RE (1968) Radiomimetric assay of acetylcholinesterase activity in submicrogram amounts of tissue. Life Sci 7:233\u2013244","journal-title":"Life Sci"},{"key":"17_CR105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0003-2697(75)90423-6","volume":"64","author":"CD Johnson","year":"1975","unstructured":"Johnson CD, Russell RL (1975) A rapid, simple radiometric assay for cholinesterase, suitable for multiple determinations. Anal Biochem 64:229\u2013238","journal-title":"Anal Biochem"},{"key":"17_CR106","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0022-510X(86)90128-0","volume":"73","author":"DM St Clair","year":"1986","unstructured":"St Clair DM, Brock DJ, Barron L (1986) A monoclonal antibody assay technique for plasma and red cell acetylcholinesterase activity in Alzheimer\u2019s disease. J Neurol Sci 73:169\u2013176","journal-title":"J Neurol Sci"},{"key":"17_CR107","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1471-4159.1992.tb09283.x","volume":"58","author":"MC Garrett","year":"1992","unstructured":"Garrett MC, Soares-da-Silva P (1992) Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington\u2019s disease: evidence for an overactive dopaminergic brain transmission. J Neurochem 58:101\u2013106","journal-title":"J Neurochem"},{"key":"17_CR108","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archpsyc.1980.01780160095011","volume":"37","author":"K Belendiuk","year":"1980","unstructured":"Belendiuk K, Belendiuk GW, Freedman DX (1980) Blood monoamine metabolism in Huntington\u2019s disease. Arch Gen Psychiatry 37:325\u2013332","journal-title":"Arch Gen Psychiatry"},{"key":"17_CR109","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/0024-3205(76)90073-4","volume":"19","author":"VK Weise","year":"1976","unstructured":"Weise VK, Kopin IJ (1976) Assay of cathecholamines in human plasma: studies of a single isotope radioenzymatic procedure. Life Sci 19:1673\u20131685","journal-title":"Life Sci"},{"key":"17_CR110","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1210\/jcem-44-5-870","volume":"44","author":"T Caraceni","year":"1977","unstructured":"Caraceni T, Panerai AE, Paratl EA et al (1977) Altered growth hormone and prolactin responses to dopaminergic stimulation in Huntington\u2019s chorea. J Clin Endocrinol Metabol 44:870\u2013875","journal-title":"J Clin Endocrinol Metabol"},{"key":"17_CR111","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/clinchem\/18.9.980","volume":"18","author":"T Nagatsu","year":"1972","unstructured":"Nagatsu T, Udenfriend S (1972) Photometric assay of dopamine-3hydroxylase activity in human blood. Clin Chem 18:980\u2013983","journal-title":"Clin Chem"},{"key":"17_CR112","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/003693307101600502","volume":"16","author":"B McNamee","year":"1971","unstructured":"McNamee B, Kelvin AS, Turnbull MJ (1971) Urinary excretion of some monoamines and metabolites in Huntington\u2019s chorea. Scott Med J 16:247\u2013249","journal-title":"Scott Med J"},{"key":"17_CR113","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0022-3565(25)26438-2","volume":"138","author":"AH Anton","year":"1962","unstructured":"Anton AH, Sayre DF (1962) A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther 138:360\u2013375","journal-title":"J Pharmacol Exp Ther"},{"key":"17_CR114","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0022-510X(71)90032-3","volume":"13","author":"HL Klawans","year":"1971","unstructured":"Klawans HL (1971) Cerebrospinal fluid homovanillic acid in Huntington\u2019s chorea. J Neurol Sci 13:277\u2013279","journal-title":"J Neurol Sci"},{"key":"17_CR115","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0024-3205(69)90428-7","volume":"8","author":"W Weiner","year":"1969","unstructured":"Weiner W, Harrison W, Klawans H (1969) l-Dopa and cerebrospinal fluid homovanillic acid in Parkinsonism. Life Sci 8:971\u2013976","journal-title":"Life Sci"},{"key":"17_CR116","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/jnnp.35.4.514","volume":"35","author":"G Curzon","year":"1972","unstructured":"Curzon G, Gumpert J, Sharpe D (1972) Amine metabolites in the cerebrospinal fluid in Huntington\u2019s chorea. J Neurol Neurosurg Psychiatry 35:514\u2013519","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"17_CR117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jnnp.33.1.1","volume":"33","author":"G Curzon","year":"1970","unstructured":"Curzon G, Godwin-Austen RB, Tomlinson EB, Kantamaneni BD (1970) The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with l-dopa. J Neurol Neurosurg Psychiatry 33:1\u20136","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"17_CR118","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-199502000-00007","volume":"18","author":"PJ Garc\u00eda Ruiz","year":"1995","unstructured":"Garc\u00eda Ruiz PJ, Mena MA, Bernardos VS et al (1995) Cerebrospinal fluid homovanillic acid is reduced in untreated Huntington\u02bcs disease. Clin Neuropharmacol 18:58\u201363","journal-title":"Clin Neuropharmacol"},{"key":"17_CR119","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/jnnp.40.6.581","volume":"40","author":"T Caraceni","year":"1977","unstructured":"Caraceni T, Calderini G, Consolazione A et al (1977) Biochemical aspects of Huntington\u2019s chorea. J Neurol Neurosurg Psychiatry 40:581\u2013587","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"17_CR120","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/0006-2952(71)90152-3","volume":"20","author":"J Korf","year":"1971","unstructured":"Korf J, van Praag HM, Sebens JB (1971) Effect of intravenously administered probenecid in humans on the levels of 5-hydroxyindoleacetic acid, homovanillic acid and 3-methoxy-4-hydroxy-phenylglycol in cerebrospinal fluid. Biochem Pharmacol 20:659\u2013668","journal-title":"Biochem Pharmacol"},{"key":"17_CR121","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s11064-008-9851-1","volume":"34","author":"M Markianos","year":"2009","unstructured":"Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2009) Plasma homovanillic acid and prolactin in Huntington\u2019s disease. Neurochem Res 34:917\u2013922","journal-title":"Neurochem Res"},{"key":"17_CR122","first-page":"254","volume":"6","author":"CM Williams","year":"1961","unstructured":"Williams CM, Maury S, Kibler RF (1961) Normal excretion of homovanillic acid in the urine of patients with Huntington\u2019s chorea. J Neurochem 6:254\u2013256","journal-title":"J Neurochem"},{"key":"17_CR123","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0009-8981(62)90022-0","volume":"7","author":"JJ Pisano","year":"1962","unstructured":"Pisano JJ, Crout JR, Abraham D (1962) Determination of 3-methoxy-4-hydroxymandelic acid in urine. Clin Chim Acta 7:285\u2013291","journal-title":"Clin Chim Acta"},{"key":"17_CR124","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0009-8981(69)90383-0","volume":"26","author":"J Korf","year":"1969","unstructured":"Korf J, Valkenburgh-Sikkema T (1969) Fluorimetric determination of 5-hydroxyindoleacetic acid in human urine and cerebrospinal fluid. Clin Chim Acta 26:301\u2013306","journal-title":"Clin Chim Acta"},{"key":"17_CR125","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archneur.1988.00520320071018","volume":"45","author":"R Kurlan","year":"1988","unstructured":"Kurlan R, Caine E, Rubin A et al (1988) Cerebrospinal fluid correlates of depression in Huntington\u2019s disease. Arch Neurol 45:881\u2013883","journal-title":"Arch Neurol"},{"key":"17_CR126","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/003693305600100402","volume":"1","author":"PS MacFarlane","year":"1956","unstructured":"MacFarlane PS, Dalgliesh CE, Dutton RW et al (1956) Endocrine aspects of argentaffinoma, with special reference to the use of urinary 5-hydroxyindoleacetic acid estimations in diagnosis. Scott Med J 1:148\u2013155","journal-title":"Scott Med J"},{"key":"17_CR127","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0006-2944(76)90031-4","volume":"16","author":"DL Murphy","year":"1976","unstructured":"Murphy DL, Wright C, Buchsbaum M et al (1976) Platelet and plasma amine oxidase activity in 680 normals: sex and age differences and stability over time. Biochem Med 16:254\u2013265","journal-title":"Biochem Med"},{"key":"17_CR128","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1096\/fj.03-0079fje","volume":"17","author":"K Varani","year":"2003","unstructured":"Varani K, Abbracchio MP, Cannella M et al (2003) Aberrant A2A receptor function in peripheral blood cells in Huntington\u2019s disease. FASEB J 17:2148\u20132150","journal-title":"FASEB J"},{"key":"17_CR129","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ajmg.b.30223","volume":"139b","author":"V Maglione","year":"2005","unstructured":"Maglione V, Giallonardo P, Cannella M et al (2005) Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington\u2019s disease. Am J Med Genet B Neuropsychiatr Genet 139b:101\u2013105","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"17_CR130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neulet.2005.09.037","volume":"393","author":"V Maglione","year":"2006","unstructured":"Maglione V, Cannella M, Martino T et al (2006) The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington\u2019s disease patients with predominant chorea. Neurosci Lett 393:27\u201330","journal-title":"Neurosci Lett"},{"key":"17_CR131","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nbd.2007.03.011","volume":"27","author":"K Varani","year":"2007","unstructured":"Varani K, Bachoud-Levi AC, Mariotti C et al (2007) Biological abnormalities of peripheral A(2A) receptors in a large representation of polyglutamine disorders and Huntington\u2019s disease stages. Neurobiol Dis 27:36\u201343","journal-title":"Neurobiol Dis"},{"key":"17_CR132","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0009-8981(62)90089-X","volume":"7","author":"JA Oates","year":"1962","unstructured":"Oates JA, Marsh E, Sjoerdsma A (1962) Studies on histamine in human urine using a fluorometric method of assay. Clin Chim Acta 7:488\u2013497","journal-title":"Clin Chim Acta"},{"key":"17_CR133","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0022-510X(81)90113-1","volume":"51","author":"BA Beutler","year":"1981","unstructured":"Beutler BA, Noronha AB, Poon MM, Arnason BG (1981) The absence of unique kainic acid-like molecules in urine, serum, and CSF from Huntington\u2019s disease patients. J Neurol Sci 51:355\u2013360","journal-title":"J Neurol Sci"},{"key":"17_CR134","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1006\/exnr.1997.6428","volume":"144","author":"R Reilmann","year":"1997","unstructured":"Reilmann R, Rolf LH, Lange HW (1997) Huntington\u2019s disease: N-methyl-d-aspartate receptor coagonist glycine is increased in platelets. Exp Neurol 144:416\u2013419","journal-title":"Exp Neurol"},{"key":"17_CR135","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.3155875","volume":"227","author":"GA Graveland","year":"1985","unstructured":"Graveland GA, Williams RS, DiFiglia M (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington\u2019s disease. Science 227:770\u2013773","journal-title":"Science"},{"key":"17_CR136","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0024-3205(80)90089-2","volume":"26","author":"NVB Manyam","year":"1980","unstructured":"Manyam NVB, Hare TA, Katz L (1980) Effect of isoniazid on cerebrospinal fluid and plasma GABA levels in Huntington's disease. Life Sci 26:1303\u20131308","journal-title":"Life Sci"},{"key":"17_CR137","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1212\/WNL.31.2.207","volume":"31","author":"G Tell","year":"1981","unstructured":"Tell G, Bohlen P, Schechter PJ, Koch-Weser J et\u00a0al (1981) Treatment of Huntington disease with \u03b3-acetylenic GABA, an irreversible inhibitor of GABA-transaminase: Increased CSF GABA and homocarnosine without clinical amelioration. Neurology 31:207\u2013207","journal-title":"Neurology"},{"key":"17_CR138","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000114017","volume":"4","author":"JHL Klawans","year":"1970","unstructured":"Klawans JHL (1970) A pharmacologic analysis of Huntington\u2019s chorea. Eur Neurol 4:148\u2013163","journal-title":"Eur Neurol"},{"key":"17_CR139","doi-asserted-by":"crossref","first-page":"11023","DOI":"10.1073\/pnas.0504921102","volume":"102","author":"F Borovecki","year":"2005","unstructured":"Borovecki F, Lovrecic L, Zhou J et\u00a0al (2005) Genome-wide expression profiling of human blood reveals biomarkers for Huntington\u2019s disease. Proc Natl Acad Sci U S A 102:11023\u201311028","journal-title":"Proc Natl Acad Sci U S A"},{"key":"17_CR140","doi-asserted-by":"crossref","first-page":"14424","DOI":"10.1073\/pnas.0703652104","volume":"104","author":"H Runne","year":"2007","unstructured":"Runne H, Kuhn A, Wild EJ et al (2007) Analysis of potential transcriptomic biomarkers for Huntington\u2019s disease in peripheral blood. Proc Natl Acad Sci U S A 104:14424\u201314429","journal-title":"Proc Natl Acad Sci U S A"},{"key":"17_CR141","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/brain\/awm312","volume":"131","author":"AN Anderson","year":"2008","unstructured":"Anderson AN, Roncaroli F, Hodges A et al (2008) Chromosomal profiles of gene expression in Huntington\u2019s disease. Brain 131:381\u2013388","journal-title":"Brain"},{"key":"17_CR142","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/mds.22477","volume":"24","author":"L Lovrecic","year":"2009","unstructured":"Lovrecic L, Kastrin A, Kobal J et\u00a0al (2009) Gene expression changes in blood as a putative biomarker for Huntington\u2019s disease. Mov Disord 24:2277\u20132281","journal-title":"Mov Disord"},{"key":"17_CR143","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1177\/147323001003800510","volume":"38","author":"L Lovrecic","year":"2010","unstructured":"Lovrecic L, Slavkov I, Dzeroski S, Peterlin B (2010) ADP-ribosylation factor guanine nucleotide-exchange factor 2 (ARFGEF2): a new potential biomarker in Huntington\u2019s disease. J Int Med Res 38:1653\u20131662","journal-title":"J Int Med Res"},{"issue":"41","key":"17_CR144","doi-asserted-by":"crossref","first-page":"17141","DOI":"10.1073\/pnas.1104409108","volume":"108","author":"Y Hu","year":"2011","unstructured":"Hu Y, Chopra V, Chopra R et al (2011) Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci U S A 108(41):17141\u201317146","journal-title":"Proc Natl Acad Sci U S A"},{"key":"17_CR145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125259","volume":"10","author":"F Cesca","year":"2015","unstructured":"Cesca F, Bregant E, Peterlin B et al (2015) Evaluating the SERCA2 and VEGF mRNAs as potential molecular biomarkers of the onset and progression in Huntington\u2019s disease. PLoS One 10:e0125259","journal-title":"PLoS One"},{"key":"17_CR146","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/hmg\/ddr111","volume":"20","author":"PM Gaughwin","year":"2011","unstructured":"Gaughwin PM, Ciesla M, Lahiri N et al (2011) Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington\u2019s disease. Hum Mol Genet 20:2225\u20132237","journal-title":"Hum Mol Genet"},{"key":"17_CR147","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2007.05.093","volume":"359","author":"CM Chen","year":"2007","unstructured":"Chen CM, Wu YR, Cheng ML et al (2007) Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington\u2019s disease patients. Biochem Biophys Res Commun 359:335\u2013340","journal-title":"Biochem Biophys Res Commun"},{"key":"17_CR148","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1074\/mcp.M800231-MCP200","volume":"8","author":"Q Fang","year":"2008","unstructured":"Fang Q, Strand A, Law W, Faca VM et al (2008) Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol Cell Proteomics 8:451\u2013466","journal-title":"Mol Cell Proteomics"},{"key":"17_CR149","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/ene.12750","volume":"22","author":"T Vinther-Jensen","year":"2015","unstructured":"Vinther-Jensen T, Simonsen AH, Budtz-J\u00f8rgensen E et al (2015) Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington\u2019s disease. Eur J Neurol 22:1378\u20131384","journal-title":"Eur J Neurol"},{"key":"17_CR150","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.410240417","volume":"24","author":"R Schwarcz","year":"1988","unstructured":"Schwarcz R, Tamminga CA, Kurlan R, Shoulson I (1988) Cerebrospinal fluid levels of quinolinic acid in Huntington\u2019s disease and schizophrenia. Ann Neurol 24:580\u2013558","journal-title":"Ann Neurol"},{"key":"17_CR151","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0304-3940(91)90874-S","volume":"122","author":"MP Heyes","year":"1991","unstructured":"Heyes MP, Swartz KJ, Markey SP, Beal MF (1991) Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington\u2019s disease. Neurosci Lett 122:265\u2013269","journal-title":"Neurosci Lett"},{"key":"17_CR152","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/brain\/115.5.1249","volume":"115","author":"MP Heyes","year":"1992","unstructured":"Heyes MP, Saito K, Crowley JS et al (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115:1249\u20131273","journal-title":"Brain"},{"key":"17_CR153","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/0024-3205(85)90223-1","volume":"37","author":"MP Heyes","year":"1985","unstructured":"Heyes MP, Garnett ES, Brown RR (1985) Normal excretion of quinolinic acid in Huntington\u2019s disease. Life Sci 37:1811\u20131816","journal-title":"Life Sci"},{"key":"17_CR154","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1471-4159.1985.tb05493.x","volume":"45","author":"AC Foster","year":"1985","unstructured":"Foster AC, Schwarcz R (1985) Characterization of quinolinic acid phosphoribosyltransferase in human blood and observations in Huntington\u2019s disease. J Neurochem 45:199\u2013205","journal-title":"J Neurochem"},{"key":"17_CR155","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1471-4159.1990.tb03143.x","volume":"55","author":"MF Beal","year":"1990","unstructured":"Beal MF, Matson WR, Swartz KJ et al (1990) Kynurenine pathway measurements in Huntington\u2019s disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 55:1327\u20131339","journal-title":"J Neurochem"},{"key":"17_CR156","first-page":"160","volume":"69","author":"WD Denckla","year":"1967","unstructured":"Denckla WD, Dewey HK (1967) The determination of tryptophan in plasma, liver, and urine. J Lab Clin Med 69:160\u2013169","journal-title":"J Lab Clin Med"},{"key":"17_CR157","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-510X(94)00280-2","volume":"130","author":"D Jauch","year":"1995","unstructured":"Jauch D, Urbanska EM, Guidetti P et al (1995) Dysfunction of brain kynurenic acid metabolism in Huntington\u2019s disease: focus on kynurenine aminotransferases. J Neurol Sci 130:39\u201347","journal-title":"J Neurol Sci"},{"key":"17_CR158","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0140-6736(89)90987-2","volume":"2","author":"GP Reynolds","year":"1989","unstructured":"Reynolds GP, Pearson SJ (1989) Increased brain 3-hydroxykynurenine in Huntington\u2019s disease. Lancet 2:979\u2013980","journal-title":"Lancet"},{"key":"17_CR159","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0304-3940(92)90749-W","volume":"144","author":"SJ Pearson","year":"1992","unstructured":"Pearson SJ, Reynolds GP (1992) Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington\u2019s disease. Neurosci Lett 144:199\u2013201","journal-title":"Neurosci Lett"},{"key":"17_CR160","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0304-3940(00)00956-3","volume":"283","author":"P Guidetti","year":"2000","unstructured":"Guidetti P, Reddy PH, Tagle DA, Schwarcz R (2000) Early kynurenergic impairment in Huntington\u2019s disease and in a transgenic animal model. Neurosci Lett 283:233\u2013235","journal-title":"Neurosci Lett"},{"key":"17_CR161","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","volume":"56","author":"S Fukui","year":"1991","unstructured":"Fukui S, Schwarcz R, Rapoport SI et al (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56:2007\u20132017","journal-title":"J Neurochem"},{"key":"17_CR162","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0028-3908(93)90171-X","volume":"32","author":"DA Jauch","year":"1993","unstructured":"Jauch DA, Sethy VH, Weick BG et al (1993) Intravenous administration of l-kynurenine to rhesus monkeys: effect on quinolinate and kynurenate levels in serum and cerebrospinal fluid. Neuropharmacology 32:467\u2013472","journal-title":"Neuropharmacology"},{"key":"17_CR163","first-page":"17","volume":"1","author":"L Vecsei","year":"1992","unstructured":"Vecsei L, Miller J, MacGarvey U, Beal F (1992) Effects of kynurenine and probenecid on plasma and brain tissue concentrations of kynurenic acid. Neurodegeneration 1:17\u201326","journal-title":"Neurodegeneration"},{"key":"17_CR164","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ana.410440322","volume":"44","author":"TJ Montine","year":"1998","unstructured":"Montine TJ, Markesbery WR, Morrow JD, Roberts LJ (1998) Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer\u2019s disease. Ann Neurol 44:410\u2013413","journal-title":"Ann Neurol"},{"key":"17_CR165","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.brainresbull.2016.12.004","volume":"133","author":"SK Barodia","year":"2016","unstructured":"Barodia SK, Creed RB, Goldberg MS (2016) Parkin and PINK1 functions in oxidative stress and neurodegeneration. Brain Res Bull 133:51\u201359","journal-title":"Brain Res Bull"},{"key":"17_CR166","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neulet.2016.04.065","volume":"636","author":"F Bozzo","year":"2017","unstructured":"Bozzo F, Mirra A, Carri MT (2017) Oxidative stress and mitochondrial damage in the pathogenesis of ALS: new perspectives. Neurosci Lett 636:3\u20138","journal-title":"Neurosci Lett"},{"key":"17_CR167","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1212\/WNL.52.5.1104","volume":"52","author":"TJ Montine","year":"1999","unstructured":"Montine TJ, Beal MF, Robertson D et al (1999) Cerebrospinal fluid F2-isoprostanes are elevated in Huntington\u2019s disease. Neurology 52:1104","journal-title":"Neurology"},{"key":"17_CR168","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/1531-8249(200012)48:6<950::AID-ANA23>3.0.CO;2-F","volume":"48","author":"TJ Montine","year":"2000","unstructured":"Montine TJ, Shinobu L, Montine K et al (2000) No difference in plasma or urinary F2-isoprostanes among patients with Huntington\u2019s disease or Alzheimer\u2019s disease and controls. Ann Neurol 48:950","journal-title":"Ann Neurol"},{"key":"17_CR169","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","volume":"66","author":"SM Hersch","year":"2006","unstructured":"Hersch SM, Gevorkian S, Marder K et al (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 66:250\u2013252","journal-title":"Neurology"},{"key":"17_CR170","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0891-5849(00)00349-X","volume":"29","author":"M Bogdanov","year":"2000","unstructured":"Bogdanov M, Brown RH, Matson W et al (2000) Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med 29:652\u2013658","journal-title":"Free Radic Biol Med"},{"key":"17_CR171","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/JHD-2012-120007","volume":"1","author":"KM Biglan","year":"2012","unstructured":"Biglan KM, Dorsey ER, Evans R et al (2012) Plasma 8-hydroxy-2\u2032-deoxyguanosine levels in Huntington disease and healthy controls treated with coenzyme Q10. J Huntingtons Dis 1:65\u201369","journal-title":"J Huntingtons Dis"},{"key":"17_CR172","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.nbd.2012.02.012","volume":"46","author":"JD Long","year":"2012","unstructured":"Long JD, Matson WR, Juhl AR et al (2012) 8OHdG as a marker for Huntington disease progression. Neurobiol Dis 46:625\u2013634","journal-title":"Neurobiol Dis"},{"key":"17_CR173","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1212\/WNL.0b013e318293e1a1","volume":"80","author":"B Borowsky","year":"2013","unstructured":"Borowsky B, Warner J, Leavitt BR et al (2013) 8OHdG is not a biomarker for Huntington disease state or progression. Neurology 80:1934\u20131941","journal-title":"Neurology"},{"key":"17_CR174","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3109\/1354750X.2014.935955","volume":"19","author":"I Ciancarelli","year":"2014","unstructured":"Ciancarelli I, De Amicis D, Di Massimo C et al (2014) Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington\u2019s patients. Biomarkers 19:452\u2013456","journal-title":"Biomarkers"},{"key":"17_CR175","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1212\/WNL.0000000000000187","volume":"82","author":"HD Rosas","year":"2014","unstructured":"Rosas HD, Doros G, Gevorkian S et al (2014) PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 82:850\u2013857","journal-title":"Neurology"},{"key":"17_CR176","first-page":"47","volume":"30","author":"I Ciancarelli","year":"2015","unstructured":"Ciancarelli I, De Amicis D, Di Massimo C et al (2015) Influence of intensive multifunctional neurorehabilitation on neuronal oxidative damage in patients with Huntington\u2019s disease. Funct Neurol 30:47\u201352","journal-title":"Funct Neurol"},{"key":"17_CR177","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.clinbiochem.2015.06.014","volume":"48","author":"M Pena-Sanchez","year":"2015","unstructured":"Pena-Sanchez M, Riveron-Forment G, Zaldivar-Vaillant T et al (2015) Association of status redox with demographic, clinical and imaging parameters in patients with Huntington\u2019s disease. Clin Biochem 48:1258\u20131263","journal-title":"Clin Biochem"},{"key":"17_CR178","first-page":"950","volume":"4","author":"MG Olsson","year":"2012","unstructured":"Olsson MG, Davidsson S, Muhammad ZD et al (2012) Increased levels of hemoglobin and alpha1-microglobulin in Huntington\u2019s disease. Front Biosci (Elite Ed) 4:950\u2013957","journal-title":"Front Biosci (Elite Ed)"},{"key":"17_CR179","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.4049\/jimmunol.161.5.2524","volume":"161","author":"V Witko-Sarsat","year":"1998","unstructured":"Witko-Sarsat V, Friedlander M, Nguyen Khoa T et al (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524\u20132532","journal-title":"J Immunol"},{"key":"17_CR180","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s00415-007-0611-y","volume":"254","author":"N Klepac","year":"2007","unstructured":"Klepac N, Relja M, Klepac R et al (2007) Oxidative stress parameters in plasma of Huntington\u2019s disease patients, asymptomatic Huntington\u2019s disease gene carriers and healthy subjects: a cross-sectional study. J Neurol 254:1676\u20131683","journal-title":"J Neurol"},{"key":"17_CR181","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1432-1033.1974.tb03714.x","volume":"47","author":"S Marklund","year":"1974","unstructured":"Marklund S, Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47:469\u2013474","journal-title":"Eur J Biochem"},{"key":"17_CR182","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0076-6879(84)05016-3","volume":"105","author":"H Aebi","year":"1984","unstructured":"Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121\u2013126","journal-title":"Methods Enzymol"},{"key":"17_CR183","first-page":"158","volume":"70","author":"DE Paglia","year":"1967","unstructured":"Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70:158\u2013169","journal-title":"J Lab Clin Med"},{"key":"17_CR184","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0021-9258(17)35986-0","volume":"261","author":"I Carlberg","year":"1986","unstructured":"Carlberg I, Mannervik B (1986) Reduction of 2,4,6-trinitrobenzenesulfonate by glutathione reductase and the effect of NADP+ on the electron transfer. J Biol Chem 261:1629\u20131635","journal-title":"J Biol Chem"},{"key":"17_CR185","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0003-2697(68)90092-4","volume":"25","author":"J Sedlak","year":"1968","unstructured":"Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman\u2019s reagent. Anal Biochem 25:192\u2013205","journal-title":"Anal Biochem"},{"key":"17_CR186","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089745","volume":"9","author":"A Carrizzo","year":"2014","unstructured":"Carrizzo A, Di Pardo A, Maglione V et al (2014) Nitric oxide dysregulation in platelets from patients with advanced Huntington disease. PLoS One 9:e89745","journal-title":"PLoS One"},{"key":"17_CR187","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0049-3848(83)90230-X","volume":"30","author":"M Radomski","year":"1983","unstructured":"Radomski M, Moncada S (1983) An improved method for washing of human platelets with prostacyclin. Thromb Res 30:383\u2013389","journal-title":"Thromb Res"},{"key":"17_CR188","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000082748","volume":"80","author":"I Banegas","year":"2004","unstructured":"Banegas I, Prieto I, Vives F et al (2004) Plasma aminopeptidase activities in rats after left and right intrastriatal administration of 6-hydroxydopamine. Neuroendocrinology 80:219\u2013224","journal-title":"Neuroendocrinology"},{"key":"17_CR189","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0022-510X(94)90134-1","volume":"127","author":"R Reilmann","year":"1994","unstructured":"Reilmann R, Rolf LH, Lange HW (1994) Huntington\u2019s disease: the neuroexcitotoxin aspartate is increased in platelets and decreased in plasma. J Neurol Sci 127:48\u201353","journal-title":"J Neurol Sci"},{"key":"17_CR190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00365738","volume":"228","author":"JS Kim","year":"1980","unstructured":"Kim JS, Kornhuber HH, Holzmuller B et al (1980) Reduction of cerebrospinal fluid glutamic acid in Huntington\u2019s chorea and in schizophrenic patients. Arch Psychiatr Nervenkr 228:7\u201310","journal-title":"Arch Psychiatr Nervenkr"},{"key":"17_CR191","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0003-2697(66)90110-2","volume":"15","author":"LT Graham Jr","year":"1966","unstructured":"Graham LT Jr, Aprison MH (1966) Fluorometric determination of aspartate, glutamate, and gamma-aminobutyrate in nerve tissue using enzymic methods. Anal Biochem 15:487\u2013497","journal-title":"Anal Biochem"},{"key":"17_CR192","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0006-8993(88)90076-5","volume":"457","author":"S Uhlhaas","year":"1988","unstructured":"Uhlhaas S, Lange H (1988) Striatal deficiency of l-pyroglutamic acid in Huntington\u2019s disease is accompanied by increased plasma levels. Brain Res 457:196\u2013199","journal-title":"Brain Res"},{"key":"17_CR193","first-page":"1582","volume":"65","author":"Huntington Study Group T-HDI","year":"2008","unstructured":"Huntington Study Group T-HDI (2008) Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 65:1582\u20131589","journal-title":"Arch Neurol"},{"key":"17_CR194","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","volume":"65","author":"BK Puri","year":"2005","unstructured":"Puri BK, Leavitt BR, Hayden MR et al (2005) Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 65:286\u2013292","journal-title":"Neurology"},{"key":"17_CR195","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/mds.26308","volume":"30","author":"JJ Ferreira","year":"2015","unstructured":"Ferreira JJ, Rosser A, Craufurd D et al (2015) Ethyl-eicosapentaenoic acid treatment in Huntington\u2019s disease: a placebo-controlled clinical trial. Mov Disord 30:1426\u20131429","journal-title":"Mov Disord"},{"key":"17_CR196","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/mds.22408","volume":"25","author":"HC Hyson","year":"2010","unstructured":"Hyson HC, Kieburtz K, Shoulson I et al (2010) Safety and tolerability of high-dosage coenzyme Q10 in Huntington\u2019s disease and healthy subjects. Mov Disord 25:1924\u20131928","journal-title":"Mov Disord"},{"key":"17_CR197","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","volume":"88","author":"A McGarry","year":"2017","unstructured":"McGarry A, McDermott M, Kieburtz K et al (2017) A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology 88:152\u2013159","journal-title":"Neurology"},{"key":"17_CR198","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","volume":"57","author":"Huntington Study Group","year":"2001","unstructured":"Huntington Study Group (2001) A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease. Neurology 57:397\u2013404","journal-title":"Neurology"},{"key":"17_CR199","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0896-6273(93)90127-D","volume":"11","author":"SH Li","year":"1993","unstructured":"Li SH, Schilling G, Young WS et al (1993) Huntington\u2019s disease gene (IT15) is widely expressed in human and rat tissues. Neuron 11:985\u2013993","journal-title":"Neuron"},{"key":"17_CR200","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","volume":"8","author":"JM Burg van der","year":"2009","unstructured":"van der Burg JM, Bjorkqvist M, Brundin P (2009) Beyond the brain: widespread pathology in Huntington\u2019s disease. Lancet Neurol 8:765\u2013774","journal-title":"Lancet Neurol"},{"key":"17_CR201","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/hmg\/8.5.813","volume":"8","author":"K Sathasivam","year":"1999","unstructured":"Sathasivam K, Hobbs C, Turmaine M et al (1999) Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 8:813\u2013822","journal-title":"Hum Mol Genet"},{"key":"17_CR202","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jnnp.39.3.244","volume":"39","author":"HJ Keogh","year":"1976","unstructured":"Keogh HJ, Johnson RH, Nanda RN, Sulaiman WR (1976) Altered growth hormone release in Huntington\u2019s chorea. J Neurol Neurosurg Psychiatry 39:244\u2013248","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"17_CR203","first-page":"551","volume":"50","author":"OT Phillipson","year":"1976","unstructured":"Phillipson OT, Bird ED (1976) Plasma growth hormone concentrations in Huntington\u2019s chorea. Clin Sci Mol Med 50:551\u2013554","journal-title":"Clin Sci Mol Med"},{"key":"17_CR204","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1136\/bmj.2.5419.1229","volume":"2","author":"M Hartog","year":"1964","unstructured":"Hartog M, Gaafar MA, Meisser B, Fraser R (1964) Immunoassay of serum growth hormone in acromegalic patients. Br Med J 2:1229\u20131232","journal-title":"Br Med J"},{"key":"17_CR205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp.41.2.135","volume":"41","author":"RJ Chalmers","year":"1978","unstructured":"Chalmers RJ, Johnson RH, Keogh HJ, Nanda RN (1978) Growth hormone and prolactin response to bromocriptine in patients with Huntington\u2019s chorea. J Neurol Neurosurg Psychiatry 41:135\u2013139","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"17_CR206","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000122878","volume":"28","author":"EE Muller","year":"1979","unstructured":"Muller EE, Parati EA, Panerai AE et al (1979) Growth hormone hyperresponsiveness to dopaminergic stimulation in Huntington\u2019s chorea. Neuroendocrinology 28:313\u2013319","journal-title":"Neuroendocrinology"},{"key":"17_CR207","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000115147","volume":"19","author":"L Murri","year":"1980","unstructured":"Murri L, Iudice A, Muratorio A et al (1980) Spontaneous nocturnal plasma prolactin and growth hormone secretion in patients with Parkinson\u2019s disease and Huntington\u2019s chorea. Eur Neurol 19:198\u2013206","journal-title":"Eur Neurol"},{"key":"17_CR208","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/jnnp.44.5.414","volume":"44","author":"PJ Lavin","year":"1981","unstructured":"Lavin PJ, Bone I, Sheridan P (1981) Studies of hypothalamic function in Huntington\u2019s chorea. J Neurol Neurosurg Psychiatry 44:414\u2013418","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"17_CR209","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/jnnp.46.12.1134","volume":"46","author":"R Durso","year":"1983","unstructured":"Durso R, Tamminga CA, Ruggeri S et al (1983) Twenty-four hour plasma levels of growth hormone and prolactin in Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 46:1134\u20131137","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"17_CR210","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.33.9.1299","volume":"33","author":"R Durso","year":"1983","unstructured":"Durso R, Tamminga CA, Denaro A et al (1983) Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington\u2019s disease. Neurology 33:1229\u20131232","journal-title":"Neurology"},{"key":"17_CR211","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/eje.0.1510451","volume":"151","author":"V Popovic","year":"2004","unstructured":"Popovic V, Svetel M, Djurovic M et al (2004) Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington\u2019s disease. Eur J Endocrinol 151:451\u2013455","journal-title":"Eur J Endocrinol"},{"key":"17_CR212","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004962","volume":"4","author":"N Saleh","year":"2009","unstructured":"Saleh N, Moutereau S, Durr A et al (2009) Neuroendocrine disturbances in Huntington\u2019s disease. PLoS One 4:e4962","journal-title":"PLoS One"},{"key":"17_CR213","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1468-1331.2009.02798.x","volume":"17","author":"NA Aziz","year":"2010","unstructured":"Aziz NA, Pijl H, Frolich M et al (2010) Growth hormone and ghrelin secretion are associated with clinical severity in Huntington\u2019s disease. Eur J Neurol 17:280\u2013288","journal-title":"Eur J Neurol"},{"key":"17_CR214","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0b013e3181e62076","volume":"75","author":"N Saleh","year":"2010","unstructured":"Saleh N, Moutereau S, Azulay JP et al (2010) High insulinlike growth factor I is associated with cognitive decline in Huntington disease. Neurology 75:57\u201363","journal-title":"Neurology"},{"key":"17_CR215","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/jnnp.2010.208553","volume":"82","author":"E Salvatore","year":"2011","unstructured":"Salvatore E, Rinaldi C, Tucci T et al (2011) Growth hormone response to arginine test differentiates between two subgroups of Huntington\u2019s disease patients. J Neurol Neurosurg Psychiatry 82:543\u2013547","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"17_CR216","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JHD-130078","volume":"2","author":"CV Russo","year":"2013","unstructured":"Russo CV, Salvatore E, Sacca F et al (2013) Insulin sensitivity and early-phase insulin secretion in normoglycemic Huntington\u2019s disease patients. J Huntingtons Dis 2:501\u2013507","journal-title":"J Huntingtons Dis"},{"key":"17_CR217","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(77)90608-0","volume":"2","author":"MR Hayden","year":"1977","unstructured":"Hayden MR, Vinik AI, Paul M, Beighton P (1977) Impaired prolactin release in Huntington\u2019s chorea. Evidence for dopaminergic excess. Lancet 2:423\u2013426","journal-title":"Lancet"},{"key":"17_CR218","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0024-3205(78)90616-1","volume":"22","author":"E Caine","year":"1978","unstructured":"Caine E, Kartzinel R, Ebert M, Carter AC (1978) Neuroendocrine function in Huntington\u2019s disease: dopaminergic regulation of prolactin release. Life Sci 22:911\u2013918","journal-title":"Life Sci"},{"key":"17_CR219","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0022-510X(89)90120-2","volume":"90","author":"HP Kremer","year":"1989","unstructured":"Kremer HP, Roos RA, Frolich M et al (1989) Endocrine functions in Huntington\u2019s disease. A two-and-a-half years follow-up study. J Neurol Sci 90:335\u2013344","journal-title":"J Neurol Sci"},{"key":"17_CR220","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2265.2010.03836.x","volume":"73","author":"NA Aziz","year":"2010","unstructured":"Aziz NA, Pijl H, Frolich M, Roelfsema F, Roos RA (2010) Altered thyrotropic and lactotropic axes regulation in Huntington\u2019s disease. Clin Endocrinol 73:540\u2013545","journal-title":"Clin Endocrinol"},{"key":"17_CR221","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/0006-3223(91)90007-9","volume":"30","author":"IJ Heuser","year":"1991","unstructured":"Heuser IJ, Chase TN, Mouradian MM (1991) The limbic-hypothalamic-pituitary-adrenal axis in Huntington\u2019s disease. Biol Psychiatry 30:943\u2013952","journal-title":"Biol Psychiatry"},{"key":"17_CR222","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0278-5846(86)90044-8","volume":"10","author":"PW Gold","year":"1986","unstructured":"Gold PW, Calabrese JR, Kling MA et al (1986) Abnormal ACTH and cortisol responses to ovine corticotropin releasing factor in patients with primary affective disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 10:57\u201365","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"17_CR223","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/bmj.1.5798.506-b","volume":"1","author":"GW Bruyn","year":"1972","unstructured":"Bruyn GW, de Yong FH, van der Molen JH (1972) Huntington\u2019s chorea and the adrenal. Br Med J 1:506","journal-title":"Br Med J"},{"key":"17_CR224","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0022-510X(95)00114-H","volume":"132","author":"F Leblhuber","year":"1995","unstructured":"Leblhuber F, Peichl M, Neubauer C et al (1995) Serum dehydroepiandrosterone and cortisol measurements in Huntington\u2019s chorea. J Neurol Sci 132:76\u201379","journal-title":"J Neurol Sci"},{"key":"17_CR225","first-page":"199","volume":"28","author":"M Markianos","year":"2007","unstructured":"Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2007) Plasma testosterone, dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington\u2019s disease. Neuro Endocrinol Lett 28:199\u2013203","journal-title":"Neuro Endocrinol Lett"},{"key":"17_CR226","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1210\/jc.2008-2543","volume":"94","author":"NA Aziz","year":"2009","unstructured":"Aziz NA, Pijl H, Frolich M et al (2009) Increased hypothalamic-pituitary-adrenal axis activity in Huntington\u2019s disease. J Clin Endocrinol Metabol 94:1223\u20131228","journal-title":"J Clin Endocrinol Metabol"},{"key":"17_CR227","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ana.20428","volume":"57","author":"M Markianos","year":"2005","unstructured":"Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2005) Plasma testosterone in male patients with Huntington\u2019s disease: relations to severity of illness and dementia. Ann Neurol 57:520\u2013525","journal-title":"Ann Neurol"},{"key":"17_CR228","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2265.2009.03661.x","volume":"73","author":"NA Aziz","year":"2010","unstructured":"Aziz NA, Pijl H, Frolich M et al (2010) Leptin secretion rate increases with higher CAG repeat number in Huntington\u2019s disease patients. Clin Endocrinol 73:206\u2013211","journal-title":"Clin Endocrinol"},{"key":"17_CR229","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/sleep\/28.12.1607","volume":"28","author":"SE Gaus","year":"2005","unstructured":"Gaus SE, Lin L, Mignot E (2005) CSF hypocretin levels are normal in Huntington\u2019s disease patients. Sleep 28:1607\u20131608","journal-title":"Sleep"},{"key":"17_CR230","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1399-0004.2006.00636.x","volume":"70","author":"M Bj\u00f6rkqvist","year":"2006","unstructured":"Bj\u00f6rkqvist M, Peters\u00e9n \u00c5, Nielsen J et\u00a0al (2006) Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease. Clin Genet 70:78\u201379","journal-title":"Clin Genet"},{"key":"17_CR231","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1002\/mds.21447","volume":"22","author":"M Bj\u00f6rkqvist","year":"2007","unstructured":"Bj\u00f6rkqvist M, Leavitt BR, Nielsen JE et al (2007) Cocaine- and amphetamine-regulated transcript is increased in Huntington disease. Mov Disord 22:1952\u20131954","journal-title":"Mov Disord"},{"key":"17_CR232","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ajmg.b.30501","volume":"144B","author":"A Ciammola","year":"2007","unstructured":"Ciammola A, Sassone J, Cannella M et al (2007) Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington\u2019s disease patients. Am J Med Genet 144B:574\u2013577","journal-title":"Am J Med Genet"},{"key":"17_CR233","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1755-5949.2008.00068.x","volume":"15","author":"F Squitieri","year":"2009","unstructured":"Squitieri F, Cannella M, Simonelli M et al (2009) Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington\u2019s disease. CNS Neurosci Ther 15:1\u201311","journal-title":"CNS Neurosci Ther"},{"key":"17_CR234","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022966","volume":"6","author":"C Zuccato","year":"2011","unstructured":"Zuccato C, Marullo M, Vitali B et al (2011) Brain-derived neurotrophic factor in patients with Huntington\u2019s disease. PLoS One 6:e22966","journal-title":"PLoS One"},{"key":"17_CR235","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/jnr.490320305","volume":"32","author":"L Lorigados","year":"1992","unstructured":"Lorigados L, Soderstrom S, Ebendal T (1992) Two-site enzyme immunoassay for beta NGF applied to human patient sera. J Neurosci Res 32:329\u2013339","journal-title":"J Neurosci Res"},{"key":"17_CR236","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nbd.2007.04.012","volume":"27","author":"N Battista","year":"2007","unstructured":"Battista N, Bari M, Tarditi A et al (2007) Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. Neurobiol Dis 27:108\u2013116","journal-title":"Neurobiol Dis"},{"key":"17_CR237","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.brainresbull.2007.12.007","volume":"76","author":"NI Wood","year":"2008","unstructured":"Wood NI, Goodman AO, van der Burg JM et al (2008) Increased thirst and drinking in Huntington\u2019s disease and the R6\/2 mouse. Brain Res Bull 76:70\u201379","journal-title":"Brain Res Bull"},{"key":"17_CR238","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archneur.65.4.476","volume":"65","author":"NM Lalic","year":"2008","unstructured":"Lalic NM, Maric J, Svetel M et al (2008) Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol 65:476\u2013480","journal-title":"Arch Neurol"},{"key":"17_CR239","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000212174","volume":"23","author":"S Podolsky","year":"1977","unstructured":"Podolsky S, Leopold NA (1977) Abnormal glucose tolerance and arginine tolerance tests in Huntington\u2019s disease. Gerontology 23:55\u201363","journal-title":"Gerontology"},{"key":"17_CR240","first-page":"163","volume-title":"Methods of enzymatic analysis","author":"A Kunst","year":"1974","unstructured":"Kunst A, Draeger B, Ziegenhorn J (1974) In: Bergmayer HU, Bergmayer J, Grassl M (eds) Methods of enzymatic analysis, vol 6. Verlag Chemie, Weinheim, pp 163\u2013172"},{"key":"17_CR241","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/clinchem\/29.2.396","volume":"29","author":"S Fraser","year":"1983","unstructured":"Fraser S, Cowen P, Franklin M et al (1983) Direct radioimmunoassay for melatonin in plasma. Clin Chem 29:396\u2013397","journal-title":"Clin Chem"},{"key":"17_CR242","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00415-009-5196-1","volume":"256","author":"NA Aziz","year":"2009","unstructured":"Aziz NA, Pijl H, Frolich M et al (2009) Delayed onset of the diurnal melatonin rise in patients with Huntington\u2019s disease. J Neurol 256:1961\u20131965","journal-title":"J Neurol"},{"key":"17_CR243","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/mds.26003","volume":"29","author":"E Kalliolia","year":"2014","unstructured":"Kalliolia E, Silajdzic E, Nambron R et al (2014) Plasma melatonin is reduced in Huntington\u2019s disease. Mov Disord 29:1511\u20131515","journal-title":"Mov Disord"},{"key":"17_CR244","doi-asserted-by":"publisher","unstructured":"Aziz NA, Onkenhout W, Kerstens HJ, Roos RA (2015) Cystathionine levels in patients with Huntington disease. PLoS Curr 7. https:\/\/doi.org\/10.1371\/currents.hd.c63b441d04bb6738c0234f91c2b3e312","DOI":"10.1371\/currents.hd.c63b441d04bb6738c0234f91c2b3e312"},{"key":"17_CR245","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1079\/BJN20051492","volume":"94","author":"W Merens","year":"2005","unstructured":"Merens W, Booij L, Markus R et al (2005) The effects of a diet enriched with alpha-lactalbumin on mood and cortisol response in unmedicated recovered depressed subjects and controls. Br J Nutr 94:415\u2013422","journal-title":"Br J Nutr"},{"key":"17_CR246","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1192\/bjp.103.432.507","volume":"103","author":"AD Forrest","year":"1957","unstructured":"Forrest AD (1957) Some observations on Huntington\u2019s chorea. J Ment Sci 103:507\u2013513","journal-title":"J Ment Sci"},{"key":"17_CR247","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1212\/WNL.15.5.455","volume":"15","author":"GW Bruyn","year":"1965","unstructured":"Bruyn GW, Mink CJ, Calje JF (1965) Biochemical studies in Huntington\u2019s chorea: erythrocyte magnesium. Neurology 15:455\u2013461","journal-title":"Neurology"},{"key":"17_CR248","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0304-3940(91)90711-2","volume":"129","author":"E Bonilla","year":"1991","unstructured":"Bonilla E, Estevez J, Suarez H et al (1991) Serum ferritin deficiency in Huntington\u2019s disease patients. Neurosci Lett 129:22\u201324","journal-title":"Neurosci Lett"},{"key":"17_CR249","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/BF02943258","volume":"163","author":"PJ Morrison","year":"1994","unstructured":"Morrison PJ, Nevin NC (1994) Serum iron, total iron binding capacity and ferritin in early Huntington disease patients. Ir J Med Sci 163:236\u2013237","journal-title":"Ir J Med Sci"},{"key":"17_CR250","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/brain\/awn212","volume":"131","author":"V Leoni","year":"2008","unstructured":"Leoni V, Mariotti C, Tabrizi SJ et al (2008) Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington\u2019s disease. Brain 131:2851\u20132859","journal-title":"Brain"},{"key":"17_CR251","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ymgme.2007.10.002","volume":"93","author":"M Markianos","year":"2008","unstructured":"Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2008) Low plasma total cholesterol in patients with Huntington\u2019s disease and first-degree relatives. Mol Genet Metab 93:341\u2013346","journal-title":"Mol Genet Metab"},{"key":"17_CR252","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neulet.2011.03.025","volume":"494","author":"V Leoni","year":"2011","unstructured":"Leoni V, Mariotti C, Nanetti L et al (2011) Whole body cholesterol metabolism is impaired in Huntington\u2019s disease. Neurosci Lett 494:245\u2013249","journal-title":"Neurosci Lett"},{"key":"17_CR253","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0009-8981(67)90269-0","volume":"16","author":"S Laurell","year":"1967","unstructured":"Laurell S, Tibbling G (1967) Colorimetric micro-determination of free fatty acids in plasma. Clin Chim Acta 16:57\u201362","journal-title":"Clin Chim Acta"},{"key":"17_CR254","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbadis.2010.05.001","volume":"1802","author":"J Kim","year":"2010","unstructured":"Kim J, Amante DJ, Moody JP et al (2010) Reduced creatine kinase as a central and peripheral biomarker in Huntington\u2019s disease. Biochim Biophys Acta 1802:673\u2013681","journal-title":"Biochim Biophys Acta"},{"key":"17_CR255","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1460-9568.2006.04985.x","volume":"24","author":"A Petersen","year":"2006","unstructured":"Petersen A, Bjorkqvist M (2006) Hypothalamic-endocrine aspects in Huntington\u2019s disease. Eur J Neurosci 24:961\u2013967","journal-title":"Eur J Neurosci"},{"key":"17_CR256","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0304-3940(02)00529-3","volume":"328","author":"F Karege","year":"2002","unstructured":"Karege F, Schwald M, Cisse M (2002) Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328:261\u2013264","journal-title":"Neurosci Lett"},{"key":"17_CR257","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.24495","volume":"78","author":"AS Lazar","year":"2015","unstructured":"Lazar AS, Panin F, Goodman AO et al (2015) Sleep deficits but no metabolic deficits in premanifest Huntington\u2019s disease. Ann Neurol 78:630\u2013648","journal-title":"Ann Neurol"},{"key":"17_CR258","unstructured":"US FDA (2001) Guidance for industry: bioanalytical method validation. Rockville, MD, USA"},{"key":"17_CR259","unstructured":"European Medicines Agency (2011) Guideline on bioanalytical method validation. London, UK"},{"key":"17_CR260","unstructured":"University College L (2017) HDClarity: a multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for Huntington\u2019s disease. https:\/\/ClinicalTrials.gov\/show\/NCT02855476"}],"container-title":["Methods in Molecular Biology","Huntington\u2019s Disease"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7825-0_17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T18:22:00Z","timestamp":1751653320000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7825-0_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9781493978243","9781493978250"],"references-count":260,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0_17","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}